X4 Pharmaceuticals Secures Licensing Deal With Norgine To Bring Mavorixafor To Europe, Australia, And New Zealand; Total Deal Value Could Exceed €254M
Benzinga Newsdesk 1 year ago
News
X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twentiesUpfront non-dilutive
- X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twenties
- Upfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's global Phase 3 clinical trial in chronic neutropenia
- Agreement underscores Norgine's commitment to bring transformative therapies to patients in need in these key strategic territories